Early in his career, Dr. Luke Nordquist realized the need for a cancer center dedicated solely to the treatment and research of Prostate & Urologic cancers. In 2010, Dr. Luke founded the Urology Cancer Center & GU Research Network in Omaha, NE. This cancer center has rapidly elevated to the level of an elite center of excellence for Prostate & Urologic Cancers. The Urology Cancer Center (UCC) was the first cancer center in the U.S. to receive government NCQA recognition for its Patient-Centered Oncology Medical Home Program and the first cancer center in its region to receive QOPI certification from the American Society of Clinical Oncology for its excellence in quality cancer care.
Through its expert focus, efficiencies, and expanding network, UCC & GU Research Network has become recognized globally by thought leaders, pharmaceutical companies, and patients as a leader in drug development through Phase 1-4 clinical trials. Dr. Luke has been the Principal Investigator on several hundred urologic cancer studies including several first-in-world treatments at UCC. Dr. Luke serves as an expert on ASCO’s guidelines panel for Advanced Prostate Cancer.
Dr. Luke started his career with a degree in Pharmacy followed by a Doctorate of Medicine, both from Creighton University. He completed a residency in Internal Medicine at the University of South Florida / H. Lee Moffitt Cancer Center in Tampa, FL. This was followed by a Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center & Medical College of Cornell in New York City. His clinical and research focus during his training was in prostate cancer and immune therapies.
Dr. Luke has surfaced as a leader in the field of radiopharmaceuticals for the treatment of prostate cancer. He has conducted several clinical trials for agents such as Ra223 and Lu177. He has been chosen as one of three sites in the U.S. for two phase 1 studies utilizing Ac225 and Th227. He enrolled the first patient globally on the VISION study with Lu177 for advance prostate cancer and accrued over 50 of the 800 total global patients for that study.
Dr. Luke is also the CEO of a Precision Cancer Research (PCR). Using experience and tools developed and realized in the GU Research program, PCR enables, oversees, and helps conduct clinical trials in community cancer centers across the U.S. This network provides the much needed access to potentially life-saving clinical trials to more cancer patients across the U.S. He realizes the vast research potential Community Cancer Centers hold, given they care for 80% of the U.S. cancer population but currently only enroll 2% of their patients on clinical trials. PCR is currently working with over 40 community cancer centers and growing. Many of these centers have the facilities, credentials, and ability to participate in radiopharmaceutical clinical trials.
Dr. Luke knows cancer patients are faced with many tough decisions and heavy burdens. He believes extensive patient education at an understandable level is at the center of excellent care and helping patients make their best decisions. Dr. Luke has served on the ASCO Government Relations Committee and is continually learning from and advocating for his patients both locally and nationally on the challenges they face and helping reduce their burdens.